US9550755, example 2;1-[2-oxo-2-[(1R,3S,5R)-3-[[1-(2,2,2-trifluoroethyl)pyrazol-3-yl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]ethyl]pyrazolo[3,4-c]pyridine-3-carboxamide
CAS
1537945-01-9
化学式
C20H19F3N8O3
mdl
——
分子量
476.418
InChiKey
SLJMBBRWVWJIRD-RTXFEEFZSA-N
BEILSTEIN
——
EINECS
——
物化性质
计算性质
ADMET
安全信息
SDS
制备方法与用途
上下游信息
反应信息
文献信息
表征谱图
同类化合物
相关功能分类
相关结构分类
计算性质
辛醇/水分配系数(LogP):
0.6
重原子数:
34
可旋转键数:
6
环数:
5.0
sp3杂化的碳原子比例:
0.4
拓扑面积:
141
氢给体数:
2
氢受体数:
9
文献信息
COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
申请人:NOVARTIS AG
公开号:US20150148374A1
公开(公告)日:2015-05-28
The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
[EN] COMPLEMENT PATHWAY MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE TRAJET DE COMPLÉMENT ET LEURS UTILISATIONS
申请人:NOVARTIS AG
公开号:WO2014009833A2
公开(公告)日:2014-01-16
The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.